Please check your internet connection and try again.
## Piperacillin/Tazobactam (Zosyn)
### Overview
Piperacillin/tazobactam is a combination penicillin-class antibiotic and beta-lactamase inhibitor. It is active against a broad spectrum of gram-positive and gram-negative bacteria, including *Pseudomonas aeruginosa*.
### Primary Indications
* Complicated intra-abdominal infections (cIAI)
* Complicated skin and skin structure infections (cSSSI)
* Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
* Community-acquired pneumonia (CAP)
* Febrile neutropenia (in combination with an aminoglycoside, though this practice is evolving)
* Management of infections caused by susceptible organisms when piperacillin alone is insufficient due to lack of spectrum or resistance mechanisms.
### Adult Dosing
* **Standard Dose:** 3.375 grams (3g piperacillin/0.375g tazobactam) intravenously (IV) every 6 hours.
* **Higher Dose (e.g., for severe infections or *Pseudomonas* coverage):** 4.5 grams (4g piperacillin/0.5g tazobactam) IV every 6 or 8 hours. Extended-infusion (e.g., 4 hours) may be considered for enhanced efficacy.
* **Maximum Dose:** Generally, 4.5 grams every 6 hours, or 3.375 grams every 4 hours. Total daily dose should not exceed 18 grams. Dosing is highly dependent on the indication and severity of infection, and local protocols should be consulted.
### Pediatric Dosing
Dosing varies significantly by age, weight, and indication. Consult specific pediatric guidelines.
* **Children < 12 years:** Generally dosed based on piperacillin component at 50 mg/kg/dose to 100 mg/kg/dose (equivalent to 57.5 mg/kg/dose to 115 mg/kg/dose of the combination product) IV every 6 to 8 hours.
* **Children ≥ 12 years:** Dosed as adults (e.g., 3.375g or 4.5g IV every 6 or 8 hours).
* **Maximum pediatric dose:** Not to exceed the maximum adult dose. Dosing in neonates and infants requires careful consideration of gestational and postnatal age.
### Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment needed.
* CrCl 20-40 mL/min: Reduce dose by 25% or increase interval to every 8 hours.
* CrCl < 20 mL/min: Reduce dose by 50% or increase interval to every 8 hours.
* Hemodialysis: Administer dose every 8 hours and supplement with an additional dose (3.375g) after each dialysis session.
### Contraindications
* Known history of severe allergic reaction to piperacillin, other beta-lactam antibiotics, or tazobactam.
### Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, injection site reactions.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome/toxic epidermal necrolysis, seizures (rare, often associated with high doses or renal impairment), neutropenia, thrombocytopenia, elevated liver enzymes.
### Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam plasma concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the anticoagulant effect of warfarin. Monitor INR closely.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels.
### Monitoring
* Renal function (baseline and during therapy).
* Liver function tests.
* Complete blood count (CBC) with differential, especially with prolonged therapy (monitor for neutropenia, thrombocytopenia).
* Signs and symptoms of infection and response to treatment.
* Electrolytes.
* INR if patient is on warfarin.
* Signs of hypersensitivity reactions.
### Clinical Pearls
* Piperacillin/tazobactam offers broad-spectrum coverage, including *Pseudomonas aeruginosa*.
* Consider extended infusion (over 4 hours) for improved efficacy, especially for severe infections or *P. aeruginosa*.
* Reconstitution and dilution guidelines are critical for stability and appropriate administration.
* The presence of tazobactam broadens the spectrum of activity against many beta-lactamase-producing organisms.
***
*This information is for educational purposes only and does not substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for specific treatment decisions.*
